Carbocyclic potential DNA minor groove binders and their biological evaluation

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 5, 2010, Pages 629-634

  Drozdowska, Danuta ^a   Bruzgo, Irena ^a   Midura Nowaczek, Krystyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Antiamidolytic activity; DNA topoisomerases; DNA binding; Netropsin; Pentamidine

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOCYCLIC MINOR GROOVE BINDER; CONGOCIDINE; DISTAMYCIN A; DNA; DNA TOPOISOMERASE; LEXITROPSIN; PENTAMIDINE; PLASMIN; POLY(DEOXYADENYLATE DEOXYTHYMIDYLATE); POLY(DEOXYGUANOSINE DEOXYCYTIDINE); POLYNUCLEOTIDE; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CELL; CANCER CELL; CELL PROLIFERATION; COLIPHAGE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA INTERACTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANILINE COMPOUNDS; BACTERIOPHAGE T4; BENZAMIDES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA, SUPERHELICAL; DNA, VIRAL; DRUG DESIGN; ETHIDIUM; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; PLASMIDS; POLYDEOXYRIBONUCLEOTIDES; SERINE PROTEINASE INHIBITORS; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 77954686276     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903389872     Document Type: Article

References (24)

1. Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat Res 2007;623:24-40.
2. Neidle S. DNA minor-groove recognition by small molecules. Nat Prod Rep 2001;18:291-309.
3. Baraldi PG, Bovero A, Fruttarolo F, Preti D, Tabrizi MA, Pavani MG, et al. DNA minor groove binders as potential antitumor and antimicrobial agents. Med Res Rev 2004;24:475-528.
4. Bailly C. Sequence-specific recognition and modification of double-helical DNA by minor-groove binding conjugates structurally related to netropsin and distamycin. In: Palumbo M, ed. Advances in DNA Sequence-Specific Agents. London: JAI Press, 1998;3:97-156.
5. Kopka ML, Yoon C, Goodsell D, Pjura P, Dickerson RE. The molecular origin of DNA-drug specificity of netropsin and distamycin. Proc Natl Acad Sci USA 1985;82:1376-1380
6. Pindur U, Jansen M, Lemster T. Advances in DNA-ligands with groove binding, intercalating and/or alkylating activity: chemistry, DNA-binding and biology. Curr Med Chem 2005;12:2805-2847
7. Bartulewicz D, Markowska A, Woczyski S, Dbrowska M, Róaski A. Molecular modelling, synthesis and antitumour activity of carbocyclic analogues of netropsin and distamycin - new carriers of alkylating elements. Acta Biochim Polon 2000;47:23-35.
8. Bartulewicz D, Bielawski K, Bielawska A, Róaski A. Synthesis, molecular modelling, and antiproliferative and cytotoxic effects of carbocyclic derivatives of distamycin with chlorambucil moiety. Eur J Med Chem 2001;36:461-467
9. Bielawski K, Bielawska A, Bartulewicz D, Róaski A. Molecular modelling of the interaction of carbocyclic analogues of netropsin and distamycin with d(CGCGAATTCGCG)2. Acta Biochim Polon 2000;47:855-866
10. Drozdowska D, Rusak M, Miltyk W, Midura-Nowaczek K. Synthesis and biological evaluation of distamycin analogues - new potential anticancer agents. Arch Pharm Chem Life Sci 2009;342:87-93.
11. Bartulewicz D, Anchim T, Midura-Nowaczek K. Synthesis and cytotoxic effect of carbocyclic potential minor groove binders. Farmaco 2004;59:211-214
12. Morgan AR, Lee JS, Pulleyblank DE, Murray NL, Evans DH. Ethidium fluorescence assays 1. Physiochemical studies. Nucleic Acids Res 1979;7:547-569
13. Debart F, Periguad C, Gosselin D, Mrani D, Rayner B, Le Ber P, et al. Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin. J Med Chem 1989;32:1074-1083
14. Schmitt M, Wilhelm OG, Reuning U, Krüger A, Harbeck N, Lengyel E, et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 2000;14:114-132
15. Andreasen PA, Kjoller L, Christensen J, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
16. Pukowska A, Midura-Nowaczek K, Bruzgo I. Effects of netropsin and pentamidine amino analogues on the amidolytic activity of plasmin, trypsin and urokinase. Acta Polon Pharm 2008;65:213-215.
17. Okada Y, Tsuda Y, Teno N, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, et al. Synthesis of active center-directed peptide inhibitors of plasmin. Chem Pharm Bull 1988;36:1289-1297
18. Tamura S, Weinhouse MI, Roberts CA, Goldman EA, Masukawa K, Anderson SM, et al. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Biorg Med Chem Lett 2000;10:983-987
19. Lown JW. Newer approaches to the study of the mechanisms of action of antitumor antibiotics. Acc Chem Res 1982;15:381-387
20. Bartulewicz D, Bielawski K, Bielawska A. Carbocyclic analogues of netropsin and distamycin: DNA-binding properties and inhibition of DNA topoisomerases. Arch Pharm Pharm Med Chem 2002;9:422-426
21. Capranico G, Borginetto ME, Cornarotti M, Zagni E, Palumbo M, Zunino F. Sequence-specific poisons of type II DNA topoisomerases. In: Palumbo M, ed. Advances in DNA Sequence-Specific Agents. London: JAI Press, 1998;3:7-38.
22. Gatto B, Fong Liu L. Topoisomerase I-targeting drugs: new developments in cancer pharmacology. In: Palumbo M, ed. Advances in DNA Sequence- Specific Agents. London: JAI Press, 1998;3:39-66.
23. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
24. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/ uPAR system in human cancers. Cancer Treat Rev 2008;34:122-136